- Provention Bio (NASDAQ:PRVB) +170% on potential of teplizumab to delay diabetes.
- Tableau Software (NYSE:DATA) +35% on being acquired by Salesforce.
- Tilray (NASDAQ:TLRY) +13% on share lock-up extension.
- Aptinyx (NASDAQ:APTX) +13% on positive NYX-2925 data in fibromyalgia.
- Pareteum (NASDAQ:TEUM) +12%.
- Beyond Meat (NASDAQ:BYND) +11%.
- Hi-Crush (NYSE:HCR) +10% on $25M stock buyback, reiterates Q2 sales volume outlook.
- MannKind (NASDAQ:MNKD) +10% on new Afrezza data.
- Domo (NASDAQ:DOMO) +9%.
- Jaguar Health (NASDAQ:JAGX) +7%.
- Reebonz Holding (NASDAQ:RBZ) +7%.
- Shutterfly (NASDAQ:SFLY) +6% as Apollo nears acquisition - Reuters.
- InflaRx N.V. (NASDAQ:IFRX) +5%.
- Redfin (NASDAQ:RDFN) +5% on two-notch upgrade.
- Uxin (NASDAQ:UXIN) +5% on Q1 results.
- Alteryx (NYSE:AYX) +5%.